ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2583

Important Role of CD11c+ Dendritic Cells in Inflammatory Arthritis

Antonia Puchner1, Victoria Saferding2, Eliana Goncalves-Alves3, Gerhard Krönke4, Rene Pfeifle4, Silvia Hayer5, Josef S. Smolen6, Kurt Redlich3,7 and Stephan Blüml3, 1Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Rheumatology, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 4Universitätsklinikum Erlangen, Erlangen, Austria, 5Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 6Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 7Medical University Vienna, Dpt. of Rheumatology, Vienna, Austria

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Arthritis, dendritic cells and mouse model

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Dendritic cells (DCs) play an important role in bridging the innate and the adaptive immune response by serving as antigen presenting cells and are therefore implicated in the initiation of chronic autoimmune diseases, including rheumatoid arthritis. Using two different models of inflammatory arthritis, K/BxN serum transfer arthritis as well as hTNFtg arthritis, both depending only on the innate immune system, we investigated the innate role of dendritic cells in inflammatory arthritis

Methods:

We analyzed histological sections of K/BxN serum transfer arthritis as well as hTNFtg arthritis for the presence of CD11c+ cells by immunohistochemistry. We also performed synovial biopsies and analyzed the cellular composition of the inflammatory infiltrate with respect to DCs. We used CD11c-diphteria toxin receptor (DTR) transgenic mice, which express the human diphtheria-toxin receptor under the CD11c promoter, allowing for specific depletion of CD11c+cells by administration of diphtheria toxin (DT).  K/BxN serum transfer arthritis was induced, and mice were given either DT or PBS or in wt and BATF3 deficient mice. In addition CD11c DTR mice were crossed into hTNFtg animals and also received either DT or PBS. The severity of arthritis was determined clinically and histologically. 

Results:

We show that Cd11c+ cells are present in significant numbers in the synovia of K/BxN and TNF driven arthritis. Both myeloid dendritic subsets, CD8+CD11c+ and CD11b+CD11c+, can be found in synovial tissue. In K/BxN serum transfer arthritis, clinical scores showed that CD11c-DTR transgenic mice that received DT had significantly reduced paw swelling and loss of grip strength compared to PBS treated animals. Histological analysis found reduced inflammation after the depletion of CD11c+ cells in K/BxN arthritis. In addition local bone destruction and the number of osteoclasts was significantly reduced. To exclude unspecific effects of DT in mice, wild type animals received DT showed identical clinical and histological signs of arthritis as PBS treated animals. Analysis of K/BxN arthritis in wt mice and BATF3-/- mice, which lack CD8+CD11+ DCs revealed no difference in arthritis severity between the two groups. In addition to K/BxN arthritis, we found that also in TNF-driven arthritis depletion of CD11c+cells led to a significant reduction of synovial inflammation, as well as local bone erosions. 

Conclusion:

These data show that in addition to initiating an adaptive immune response, CD11c+ dendritic cells are also involved in innate effector mechanisms of inflammatory arthritis and suggest that dendritic cells could be an important therapeutic target for patients suffering from inflammatory arthritis.


Disclosure: A. Puchner, None; V. Saferding, None; E. Goncalves-Alves, None; G. Krönke, None; R. Pfeifle, None; S. Hayer, None; J. S. Smolen, AbbVie, Janssen, Eli Lilly and Company, MSD, Pfizer, Roche, 2,Abbvie, Amgen, Astra-Zeneca, Astro, Celgene, Glaxo, ILTOO, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Novo-Nordisk, Pfizer, Roche, Samsung, Sanofi, UCB, 5; K. Redlich, None; S. Blüml, None.

To cite this abstract in AMA style:

Puchner A, Saferding V, Goncalves-Alves E, Krönke G, Pfeifle R, Hayer S, Smolen JS, Redlich K, Blüml S. Important Role of CD11c+ Dendritic Cells in Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/important-role-of-cd11c-dendritic-cells-in-inflammatory-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/important-role-of-cd11c-dendritic-cells-in-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology